November 11, 2021
SymBio Pharmaceuticals Limited(Securities Code: 4582)
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021
Financial Overview for the Third Quarter of the Fiscal Year Ending December 31, 2021

SymBio Pharmaceuticals Limited (Headquarters: Tokyo, Japan, "SymBio" or the “Company”)
today announced its financial results for the third quarter of the fiscal year ending December 31,
2021. SymBio has achieved operating profit for two consecutive quarters in the second and thirdquarters of the current fiscal year.
Highlights of Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2021
In the third quarter of the fiscal year, the Company made gradual progress in remediating effectsof treatment delays due to countermeasures against COVID-19, such as vaccination of elderly
patients. In addition, the approval of BR therapy and P-BR therapy for relapsed or refractory
diffuse large B-cell lymphoma ("r/r DLBCL") on March 23, 2021 and the NHI drug price listing ofpolatuzumab vedotin by Chugai Pharmaceutical Co. Ltd. on March 19, 2021 contributed to theincrease in sales. As a result, net sales for the third quarter increased by 680 million yen from thesecond quarter to 2,406 million yen, and operating income increased by 603 million yen from thesecond quarter to 619 million yen.
In the first nine months of the current fiscal year, net sales were 5,553 million yen and operating
income was 424 million yen.
Progress of major milestones since the announcement of the second quarter results
First Patient Dosed in Phase II clinical trial for BCV IVOn August 16, 2021 (Pacific Daylight Time in USA), we achieved First Patient Dosed in the global
Phase II clinical trial of an intravenous formulation of the anti-viral drug brincidofovir (BCV IV)
for treatment of pediatric adenovirus infection.
Related press release: https://www.symbiopharma.com/news_e/20210817e.pdf
Initiation of controls on shipment of TREAKISYM® FD Formulation
On September 21, 2021, due to delays in conversion from TREAKISYM® freeze-dry lyophilized
injection formulation ("FD") to ready-to-dilute liquid formulation ("RTD") and the possibility of a
supply shortage of FD, the Company initiated controls on shipments of FD. However, with theunderstanding and cooperation of health care professionals, the conversion to RTD formulation
has progressed rapidly.
Related press release: https://www.symbiopharma.com/news_e/20210921e.pdf

SymBio Pharma USA, Inc. begins Operations
On October 11, 2021 (Pacific Daylight Time in USA), Dr. Carolyn Yanavich was appointed as theVice President, and Head of Project Management and Clinical Operations of SymBio Pharma USA,Inc. (“SymBio Pharma USA”), the Company’s wholly-owned U.S. subsidiary. This appointment will
enable SymBio Pharma USA to begin operations and is expected to further accelerate the global
business development of BCV IV. It is a significant step in the Company's transformation into a
global specialty pharmaceutical company.
Related press release: https://www.symbiopharma.com/news_e/20211012e.pdf
Message from Dr. Carolyn Janavich: https://www.symbiopharma.com/vision_e/09.html
Quarterly and Cumulative Results for the Fiscal Year Ended December 31, 2021

(million yen)

5,553

5,000

2,406
2,000

1,726
1,420

1,0006190△ 210Jan.-Mar.
-1,000[Contact]
Investor Relations
Tel: +81(0)3 5472 1125

424

15

Apr.-Jun.

Jul.-Sept.

Cumulative total
for Jan.-Sept